Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

The new multi-targeted agent Curaxin-137 suppresses mammary tumorigenesis in Her2/neu transgenic mice

ABSTRACT: Global gene expression profiles in liver and spleen between Curaxin-treated and control mice Gene expression profiles of samples isolated from 2 mice in each treatment group, control (plain water), and treated 0.1 and 0.2 mg/ml of Curaxin-137 from 4 to 14 weeks of age. Liver and spleen RNAs were analyzed

ORGANISM(S): Mus musculus

SUBMITTER: Dan Wang

PROVIDER: E-GEOD-33285 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.

Koman Igor E IE Commane Mairead M Paszkiewicz Geraldine G Hoonjan Bhupinder B Pal Srabani S Safina Alfiya A Toshkov Ilya I Purmal Andrei A AA Wang Dan D Liu Song S Morrison Carl C Gudkov Andrei V AV Gurova Katerina V KV

Cancer prevention research (Philadelphia, Pa.) 20120611 8

Development of safe and effective tumor-preventive treatments for high-risk patient populations and therapies for early-stage cancer remains a critical need in oncology. We have recently discovered compound with anticancer activity, Curaxin-137, which modulates several important signaling pathways involved in even the very early stages of cancer. In tumor cells, Curaxin-137 inhibits NF-κB- and HSF1-dependent transcription (prosurvival pathways) and activates p53 (a proapoptotic pathway) without ...[more]

PMID: 22689915

Similar Datasets

Project description:Purpose: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. Experimental design: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. Results: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate â¤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. Conclusions and clinical relevance: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for MRM-MS. The availability of these datasets will contribute positively to clinical proteomics. Affymetrix GeneChip Mouse Genome 430 2.0 microarrays were used to profile whole tissues from 5 different tissue types of 25 tumor-bearing and 25 control mice of the Her2/Neu breast cancer mouse model. The 5 tissues tested were from breast, liver, spleen, blood cell, and thymus. The tumor-bearing mice were bitransgenic for MMTV-rtTA/TetO-NeuNT, and the control mice were transgenic for TetO-NeuNT only. The control mice were age- and cage-matched to the tumor-bearing mice. All samples were lysed and total RNA isolated and amplified prior to hybridization.

Dataset Information

The new multi-targeted agent Curaxin-137 suppresses mammary tumorigenesis in Her2/neu transgenic mice

Publications

Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure